Skip to main content
. Author manuscript; available in PMC: 2011 Jun 13.
Published in final edited form as: Clin Gastroenterol Hepatol. 2008 Jul 10;6(11):1206–1211. doi: 10.1016/j.cgh.2008.04.031

Table 1.

Patient characteristics by treatment modality

Esophagectomy Ablation P value
N 79 80
Age at treatment 63.1 ± 10.6 69.7 ± 9.4 <0.0001
Male gender 73 (92%) 64 (80%) 0.02
Vital status: deceased 10 (13%) 8 (10%) 0.60
Length BE (in cm)* 6.6 ± 3.7 5.4 ± 3.7 0.03
Co-morbid diagnoses
CAD 19 (24%) 21 (26%) 0.75
CHF 6 (8%) 5 (6%) 0.74
COPD 5 (6%) 9 (11%) 0.27
Cancer stage
HGD/IMC 28 (35%) 70 (88%) <0.0001
T1sm 8 (10%) 6 (8%)
T2 or greater 43 (54%) 4 (5%)
Initial consultant
Gastroenterologist 32 (41%) 76 (95%) <0.0001
Surgeon 42 (53%) 4 (5%)
Oncologist 5 (6%) 0
*

Pre-treatment length of Barrett’s esophagus not recorded in 24 patients in esophagectomy group, and 4 patients in ablation group.